These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 7378252)

  • 21. Bioavailability of sustained-release theophylline formulations.
    Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissolution and bioavailability studies of whole and halved sustained-release theophylline tablets.
    Simons KJ; Frith EM; Simons FE
    J Pharm Sci; 1982 May; 71(5):505-11. PubMed ID: 7097493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of steady state serum theophylline concentrations in healthy volunteers after dosing with Euphyllin retard and PulmiDur.
    Karlsson S; Lührmann B; Bahner ML; Schulz HU
    Int J Clin Pharmacol Ther Toxicol; 1987 Jun; 25(6):342-6. PubMed ID: 3623739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inconsistent absorption from a sustained-release theophylline preparation during continuous therapy in asthmatic children.
    Rogers RJ; Kalisker A; Wiener MB; Szefler SJ
    J Pediatr; 1985 Mar; 106(3):496-501. PubMed ID: 3973788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a new sustained-release theophylline tablet for children.
    Selvig K; Alme A; Rugstad HE; Aas K; Bjerve KS
    Acta Paediatr Scand; 1981 Nov; 70(6):929-33. PubMed ID: 7324949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing.
    Schulz HU; Steinijans VW; Gabel H
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):621-5. PubMed ID: 6500759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability and diurnal variation in absorption of sustained release theophylline in asthmatic children.
    Coulthard KP; Birkett DJ; Lines DR; Grgurinovich N; Grygiel JJ
    Eur J Clin Pharmacol; 1983; 25(5):667-72. PubMed ID: 6686557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
    Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
    Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo sustained-release characteristics of theophylline matrix tablets and novel cluster tablets.
    Hayashi T; Kanbe H; Okada M; Kawase I; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
    Int J Pharm; 2007 Aug; 341(1-2):105-13. PubMed ID: 17512147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of food on the absorption of theophylline from a sustained release formulation (Somophyllin).
    Pedersen S; Møller-Petersen J
    Clin Allergy; 1985 May; 15(3):253-9. PubMed ID: 4006175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of steady state plasma theophylline concentrations with conventional and sustained release formulations.
    Mellstrand T; Svedmyr K; Svedmyr N
    Eur J Respir Dis; 1982 Jan; 63(1):31-4. PubMed ID: 7040098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of sustained release theophylline in low and high multidose regimens.
    Koëter GH; Jonkman JH; de Vries K; Schoenmaker R; Greving JE; de Zeeuw RA
    Br J Clin Pharmacol; 1981 Nov; 12(5):647-51. PubMed ID: 7332728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steady-state pharmacokinetics and effects of a new once-daily, slow-release theophylline capsule preparation in asthma.
    Williams PE; Alwazir YA; Routledge PA; Campbell IA
    Br J Clin Pharmacol; 1986 Oct; 22(4):383-7. PubMed ID: 3768254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic disposition of an immediate-release aminophylline and a sustained-release theophylline formulation in the horse.
    Goetz TE; Munsiff IJ; McKiernan BC
    J Vet Pharmacol Ther; 1989 Dec; 12(4):369-77. PubMed ID: 2614856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of charcoal and sorbitol (alone and in combination) on plasma theophylline concentrations after a sustained-release formulation.
    al-Shareef AH; Buss DC; Allen EM; Routledge PA
    Hum Exp Toxicol; 1990 May; 9(3):179-82. PubMed ID: 2375885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of a sustained-release theophylline preparation in healthy subjects.
    Goto M; Nakamoto Y; Sugiyama M; Yamashina H
    J Pharmacobiodyn; 1983 Apr; 6(4):225-31. PubMed ID: 6620110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioavailability of a sustained-release dyphylline formulation.
    Simons KJ; Simons FE; Bierman CW
    J Clin Pharmacol; 1977 Apr; 17(4):237-41. PubMed ID: 849997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a new sustained release theophylline formulation by the measurements of salivary levels of the drug in humans.
    Nakano M; Nakamura Y; Juni K; Tomitsuka T
    J Pharmacobiodyn; 1980 Dec; 3(12):702-8. PubMed ID: 7277185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.